CA2457781A1 - Kgf polypeptide compositions - Google Patents

Kgf polypeptide compositions Download PDF

Info

Publication number
CA2457781A1
CA2457781A1 CA002457781A CA2457781A CA2457781A1 CA 2457781 A1 CA2457781 A1 CA 2457781A1 CA 002457781 A CA002457781 A CA 002457781A CA 2457781 A CA2457781 A CA 2457781A CA 2457781 A1 CA2457781 A1 CA 2457781A1
Authority
CA
Canada
Prior art keywords
kgf
amino acid
inclusive
amount
acid residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002457781A
Other languages
English (en)
French (fr)
Inventor
Denis J. Gospodarowicz
W. Michael Kavanaugh
Kenneth Crawford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23217561&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2457781(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2457781A1 publication Critical patent/CA2457781A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA002457781A 2001-08-21 2002-08-21 Kgf polypeptide compositions Abandoned CA2457781A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31388101P 2001-08-21 2001-08-21
US60/313,881 2001-08-21
PCT/US2002/026929 WO2003016505A2 (en) 2001-08-21 2002-08-21 Kgf polypeptide compositions

Publications (1)

Publication Number Publication Date
CA2457781A1 true CA2457781A1 (en) 2003-02-27

Family

ID=23217561

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002457781A Abandoned CA2457781A1 (en) 2001-08-21 2002-08-21 Kgf polypeptide compositions

Country Status (8)

Country Link
US (2) US7265089B2 (cg-RX-API-DMAC7.html)
EP (1) EP1429799A4 (cg-RX-API-DMAC7.html)
JP (2) JP2005500390A (cg-RX-API-DMAC7.html)
AU (1) AU2002326742B2 (cg-RX-API-DMAC7.html)
CA (1) CA2457781A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA04001526A (cg-RX-API-DMAC7.html)
PL (1) PL374269A1 (cg-RX-API-DMAC7.html)
WO (1) WO2003016505A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012000865A2 (pt) * 2009-07-17 2019-09-24 T Tabor Aaron "composição e método para a modificação genética cosmética de células substancialmente intactas"
US20160250298A1 (en) 2013-11-01 2016-09-01 Spherium Biomed S.L. Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents
TW201613622A (en) * 2014-10-14 2016-04-16 Bionet Corp Composition for skincare and pharmaceutical composition and preparation method thereof
CN109402130A (zh) * 2018-11-23 2019-03-01 成都中医药大学附属医院 一种重组人角质细胞生长因子-1及其制备方法和用途
KR20230127721A (ko) * 2022-02-25 2023-09-01 한국해양과학기술원 온도안정성을 향상시킨 fgf7 폴리펩타이드 및 그 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0555205T3 (da) 1989-01-31 2001-03-05 Jeffrey S Rubin DNA, der koder for en væstfaktor, som er specifik for epitelceller
US5194596A (en) 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5655870A (en) * 1993-03-01 1997-08-12 Kawasaki Steel Corporation Stacker crane in a warehouse
US5814605A (en) 1993-03-26 1998-09-29 Amgen Inc. Therapeutic uses of keratinocyte growth factor
NZ266622A (en) 1993-06-29 1997-10-24 Chiron Corp Keratinocyte growth factor fragment (kgf) with at least a 2-fold increase in mitogenic activity compared to a full length kgf; dna molecules, expression vectors, host cells, and conjugates
SI0785950T1 (en) 1994-10-13 2003-08-31 Amgen Inc. Keratinocyte growth factor analogs
EP0804479B1 (en) * 1994-10-13 2006-10-11 Amgen Inc., Method of treating diabetes mellitus using kgf
DK0785949T3 (da) * 1994-10-13 2003-08-18 Amgen Inc Fremgangsmåde til oprensning af keratinocytvækstfaktorer
US5841605A (en) * 1996-11-06 1998-11-24 Iomega Corporation Caddy for cartridge and disk drive accomodating a caddy
ES2181054T3 (es) * 1996-12-06 2003-02-16 Amgen Inc Utilizacion de producto(s) proteico(s) kgf y de producto(s) proteico(s) glp-2 para la preparacion de un medicamento.

Also Published As

Publication number Publication date
JP2009221207A (ja) 2009-10-01
JP2005500390A (ja) 2005-01-06
US7265089B2 (en) 2007-09-04
PL374269A1 (en) 2005-10-03
WO2003016505A2 (en) 2003-02-27
US20080200378A1 (en) 2008-08-21
EP1429799A4 (en) 2005-12-21
MXPA04001526A (es) 2004-05-31
US20030109439A1 (en) 2003-06-12
WO2003016505A3 (en) 2004-01-08
EP1429799A2 (en) 2004-06-23
AU2002326742B2 (en) 2007-05-31

Similar Documents

Publication Publication Date Title
EP1751184B1 (en) Fgf-21 fusion proteins
CN100528235C (zh) 红细胞生成素共轭物
JP6181752B2 (ja) 線維芽細胞増殖因子21変異体
PT99565B (pt) Processo para a preparacao de factores de crescimento de fibroblastos quimerico s
US20070265200A1 (en) Glycol Linked Fgf-21 Compounds
AU2005283025A1 (en) Muteins of fibroblast growth factor 21
EP1831371A2 (en) Muteins of fibroblast growth factor 21
JPH05503003A (ja) 潜在性関与ペプチドおよびその使用
AU6894291A (en) Non-glycosylated fgf-4 and compositions containing the same
AU3707795A (en) Analogs of keratinocyte growth factor
US5736363A (en) IGF-II analogues
US20080200378A1 (en) KGF polypeptide compositions
AU2002326742A1 (en) KGF polypeptide compositions
EP1961821B1 (en) Erythropoietin fusion protein
AU2007214362B2 (en) KGF polypeptide compositions
JPWO2009116529A1 (ja) ポリペプチドおよび当該ポリペプチドを含む医薬組成物
CA2079291A1 (en) Activities of heparin binding neurite-outgrowth promoting factor
WO2002060163A2 (en) Methods for increasing bone formation and enhancing bone accretion
MXPA97002475A (en) Analogues of the fibroblast acid growth factor that have stability and biological acticity improves
JPH06183993A (ja) 好中球減少症治療剤

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued